Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDFPe Dose-finding in Acute Ischemic Stroke
NCT02963376Phase 1Completed
- Sponsor
- NuvOx Therapeutics
- Start
- Feb 2017
- Primary completion
- Jul 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of perflenapent in ischemic stroke (6 arms), sponsored by NuvOx Therapeutics. Primary endpoint: Maximum Tolerated Dose at 12 hours. Started Feb 2017; status: completed.
02
Drugs
perflenapent
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02963376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963376.